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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYInterleukin-3 (IL-3) is capable of supporting the proliferation of a broad range of hematopoietic cell types, whereas granulocyte colony-
stimulating factor (G-CSF) and macrophage CSF (M-CSF) represent critical cytokines in myeloid differentiation. When this was
investigated in a pluripotent-stem-cell-based hematopoietic differentiation model, IL-3/G-CSF or IL-3/M-CSF exposure resulted in the
continuous generation of myeloid cells from an intermediate myeloid-cell-forming complex containing CD34+ clonogenic progenitor
cells formore than 2months.Whereas IL-3/G-CSF directed differentiation towardCD45+CD11b+CD15+CD16+CD66b+ granulocytic cells
of various differentiation stages up to a segmented morphology displaying the capacity of cytokine-directed migration, respiratory burst
response, and neutrophil-extracellular-trap formation, exposure to IL-3/M-CSF resulted in CD45+CD11b+CD14+CD163+CD68+ mono-
cyte/macrophage-type cells capable of phagocytosis and cytokine secretion. Hence, we show here that myeloid specification of human
pluripotent stem cells by IL-3/G-CSF or IL-3/M-CSF allows for prolonged and large-scale production ofmyeloid cells, and thus is suited for
cell-fate and disease-modeling studies as well as gene- and cell-therapy applications.INTRODUCTION
Hematopoietic in vitro differentiation of pluripotent stem
cells (PSCs) such as embryonic stem cells (ESCs) and
induced PSCs (iPSCs) holds great promise for disease
modeling, drug testing, and the development of novel
cell- and gene-therapy strategies. In the past, interest has
been directed primarily toward reconstituting stem cells,
a cell type that is difficult to generate from PSC sources.
Recently, however, long-lived, mature myeloid cells have
been described (Guilliams et al., 2013), and the organo-
tropic transplantation of such cells may allow for new ther-
apeutic scenarios (Happle et al., 2014; Suzuki et al., 2014).
During embryonic development, hematopoietic cells
are generated by two distinct but partly overlapping pro-
grams termed primitive and definitive hematopoiesis.
Both are orchestrated by a highly complex interaction
of regulatory molecules, including transcription factors,282 Stem Cell Reports j Vol. 4 j 282–296 j February 10, 2015 j ª2015 The Acytokine-induced and intercellular signaling, andniche fac-
tors (Lancrin et al., 2009; Nostro et al., 2008; Sturgeon et al.,
2014). Primitive hematopoietic development originates
from distinct multipotent precursors known as hemangio-
blasts, which are able to generate both vascular and
hematopoietic progeny via an intermediate, hemogenic
endothelial stage (Lancrin et al., 2009). Subsequently,
further hematopoietic specification and differentiation
result in mature cells that are primarily of an erythroid
and, to a lesser degree, myeloid lineage (Palis, 2014; Schulz
et al., 2012). In a separate process originating in the dorsal
aorta, definitive hematopoiesis allows for the generation
of transplantable hematopoietic stem cells (HSCs) that are
capable of repopulating the entire lympho-hematopoietic
system long term. In this context, an important role for
the cytokine interleukin-3 (IL-3) (Donahue et al., 1988;
Robin et al., 2006; Wiles and Keller, 1991) as well as wnt
signaling (Sturgeon et al., 2014) has been reported by authors
number of groups. Again, the fate of these repopulating
HSCs, such as self-renewal, apoptosis, quiescence, and
further differentiation and proliferation, is dependent on
their exposure to other cells, matrix factors, or cytokines
(Arai et al., 2004; Williams et al., 1991). For both programs,
granulocyte-colony-stimulating factor (G-CSF) and mono-
cyte-CSF (M-CSF) constitute the main driving forces for
the generation and terminal differentiation of functional
cells of a granulocytic or monocytic/macrophage lineage,
respectively (Sengupta et al., 1988; Welte et al., 1985a,
1987).
G-CSF originallywas identified by its capacity to promote
the differentiation of human bonemarrow progenitor cells
toward neutrophils and is a critical component of this pro-
cess (Welte et al., 1985b, 1987). However, the G-CSF recep-
tor (CSF3R) is not exclusive to myeloid cells and has also
been identified on HSCs, thus explaining the profound
stem cell defects observed in congenital neutropenia pa-
tients suffering from defects in G-CSF signaling (Panopou-
los and Watowich, 2008). In contrast, M-CSF, the crucial
cytokine for generating mononuclear phagocytes or mac-
rophages (MF) from HSC sources, appears to be primarily
involved in terminal lineage differentiation (Yoshida
et al., 1990). M-CSF was the first hematopoietic cytokine
to be identified and cloned, and acts by activating its type
III protein tyrosine kinase family receptor (c-fms) (Clark
and Kamen, 1987; Sieff, 1987). Generating MF by M-CSF
exposure, similarly to priming with IL-4/IL-10, results in
alternatively activated M2-type F, in contrast to the
classical pro-inflammatory M1F, which is differentiated
frommonocytes by GM-CSF or interferon-gamma (IFNg)
exposure (Martinez et al., 2008; Sica andMantovani, 2012).
To date,most protocols for hematopoietic differentiation
of PSCs in vitro have utilized a multitude of cytokines or
small molecules to mimic the modulation of signaling
pathways at various stages of embryonic development
(Choi et al., 2011; Kennedy et al., 2012; Sturgeon et al.,
2014). However, many of the factors involved in this pro-
cess remain ill defined. Therefore, this excessive priming
may have unwanted effects on the differentiation or func-
tionality of the desired target cells, hampering their use in
disease modeling or cell- and gene-therapy applications.
Thus, the development of simple but robust protocols for
generating nonbiased and fully functional hematopoietic
cells appears to be highly warranted.
Given the (1) emerging role of IL-3 in early primitive as
well as definitive hematopoietic specification (Donahue
et al., 1988; Robin et al., 2006; Yang et al., 1986), (2) the
fundamental importance of G-CSF and M-CSF in terminal
granulocyte and monocyte/macrophage differentiation
(Clark and Kamen, 1987; Sengupta et al., 1988; Sieff, 1987;
Welte et al., 1987), and (3) the synergy reported between
IL-3 and late-acting factors such as G-CSF, M-CSF, and gran-Stem Cellulocyte-macrophage CSF (GM-CSF) (Donahue et al., 1988;
Wiles and Keller, 1991), we sought to investigate the com-
bined use of IL-3 with either M-CSF or G-CSF, employing
embryoid body (EB)-based hematopoietic in vitro differen-
tiation. For this purpose, we developed an innovative
protocol that allows for the prolonged and large-scale pro-
duction of functional granulocytes as well as monocytes/
macrophages. Generation of immature myeloid cells was
mediatedbyan intermediatemyeloid-cell-formingcomplex
(MCFC) containing CD34+ clonogenic progenitor cells,
which upon continuedG-CSF orM-CSF exposure generated
terminally differentiated myeloid cells for R2 months. As
generation of these cells was accomplished by exposure of
PSCs to IL-3 and one additional cytokine only, this protocol
can be expected to closely recapitulate many aspects of
physiologic hematopoietic development. Thus, it may be
particularly suitable for studying human hematopoietic
development in vitro and generating mature functional
cells for cell and gene therapy.RESULTS
Hematopoietic Specification of Human iPSCs
To investigate the effect of IL-3/G-CSF or IL-3/M-CSF on
hematopoietic in vitro differentiation of PSCs, we estab-
lished a four-step differentiation protocol (Figure 1A)
utilizing human iPSCs (hiPSCs) previously generated from
nonmobilized peripheral blood (PB)-derived CD34+ cells
(hCD34iPSC11 and hCD34iPSC16) (Ackermann et al.,
2014; Lachmann et al., 2014) or the human ESC line H9.
To initiate differentiation, iPSCs were cultured on mouse
feeder cells in the presence of basic fibroblast growth factor
(bFGF), resulting in typical round-shaped colonies (Fig-
ure 1B, step 1). Induction of germ layer formation was
induced within EBs for 5 days (d0–d5) by orbital shaking
and reduction of bFGF concentrations by 4-fold. After
5 days, we obtained compact and spherical EB cells
(Figure 1B, step 2), which showed a slight decrease in
TRA1-60 expression (Figure 1C). Induction of mesoderm
was confirmed by decreased expression levels of OCT4
(POU5F1) as well as increased expression of Brachyury (T)
mRNAwhen compared with the original iPSCs (Figure 1D).
Fromd0onward, EBswere subjected todirectedhematopoi-
etic specification by usingmedium supplementedwith IL-3
and either G-CSF orM-CSF. Culture of EBs under these con-
ditions for 10–15days resulted in the formationof endothe-
lial-like stromal cells and MCFCs (Figure 1B, step 3). The
stromal cells had endothelial structure (Figure S1A) and
stained positive for CD31, CD309 (Flk1), and CD144 (VE-
Cadherin),whereas cells isolated fromMCFCs stainednega-
tive forCD31,CD309, andCD144 (Figure S1B). For the IL-3/
M-CSF combination, hematopoietic specification withinReports j Vol. 4 j 282–296 j February 10, 2015 j ª2015 The Authors 283
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Figure 1. Four-Step Hematopoietic Differentiation Protocol for Human PSCs
(A) Schematic representation of the four-step hematopoietic differentiation protocol. Human PSCs were cultured on irradiated mouse
feeder cells (step 1). Formation of EBs was induced by cultivating fragmented colonies in suspension plates on an orbital shaker (step 2).
After 5 days, the largest EBs were manually selected under a binocular microscope and further cultured on adherent plates in differen-
tiation medium I supplemented with either IL-3/G-SCF or IL-3/M-CSF for hematopoietic specification (step 3). From d10–d15 onward,
granulocytes or monocyte/macrophages were generated by the MCFC. For terminal differentiation, cells were cultivated for another 7 days
in differentiation medium II supplemented with G-CFS or M-CSF, leading to iPSC-MF or iPSC-Gra, respectively (step 4).
(B) Representative light microscopy images of steps 1–3 of hematopoietic differentiation (scale bars, 500 mM and 200 mM).
(C) Surface expression of Tra-1-60 (gray filled) in iPSCs and EBs determined by flow cytometry (black, respective isotype control).
(D) Expression of OCT4, Brachyury (T), PTPRC, and RUNX1 at different stages of differentiation (iPSCs, EBs [d0] in MCFCs at days 4, 8, and 12,
and in terminally differentiated iPSC-MF) determined by quantitative RT-PCR analysis (expression normalized to undifferentiated iPSCs.
GAPDH was used as a housekeeping control; n = 2 of independent experiments, mean ± SD). Data are shown for hCD34iPSC16.
See also Figures S1 and S2.the MCFCs was demonstrated by a gradual reduction in
expression of pluripotency (OCT4) and mesodermal (T)
markers, whereas mRNA levels for the hematopoietic
markers CD45 (PTPRC) and RUNX1 gradually increased
during the differentiation process. Of note, the formation
of endothelial-like stromal cells served as a reliable quality
criterion for the subsequent success ofhematopoietic differ-
entiation (Figure S1).284 Stem Cell Reports j Vol. 4 j 282–296 j February 10, 2015 j ª2015 The AFurther cultivation of the MCFCs in differentiation me-
dium led to the continuous release of round-shaped sus-
pension cells from the MCFCs from d12–d16 onward (Fig-
ure 1B, step 3). Remarkably, continuous shedding of cells
from the MCFCs was observed for both the IL-3/G-CSF
and IL-3/M-CSF combinations, for a period of 2–3 months.
Furthermore, cells generatedwith IL-3/M-CSF showed high
levels of PTPRC as well as RUNX1mRNA from d12 onward,uthors
suggesting that these cells were of a hematopoietic lineage
(Figure 1D). Of note, expression of PTPRC was also
confirmed by flow cytometry, which demonstrated cells ex-
pressing CD45 as early as d8. In this context, cells appear-
ing on d5 expressed CD34 only, whereas on d8 CD34+ cells
became double positive for CD34 and CD45 (Figure S2A).
Furthermore, when d8 CD34/CD45 double-positive cells
were isolated fromEBs and sorted by fluorescence-activated
cell sorting (FACS) for additional evaluation of CD144
expression, only the CD144 fraction gave rise to myeloid
colonies in semisolid medium (Figure S2B). Interestingly,
almost no shedding of cells from MCFCs was observed
for cultures grown in G-CSF alone (data not shown). As
both M-CSF and G-CSF represent potent cytokines for the
terminal differentiation of granulocytes and monocytes/
macrophages, respectively, cells that shed from MCFCs
were subsequently differentiated in the presence of a
high concentration of G-CSF or M-CSF only for an addi-
tional 7 days (Figure 1A, step 4).
M-CSF Directs hiPSCs toward an M2-like Macrophage
Phenotype
In vivo,monocytes that have differentiated fromHSC sour-
ces can be polarized to eitherM1 orM2macrophages (M1F
and M2F, respectively), which play distinct roles within
the immunoregulatory network. M1F (also known as
classical or pro-inflammatory MF) are activated by IFN-g,
lipopolysaccharide (LPS), certain viruses, or GM-CSF, and
promote TH1- or TH17-mediated immune responses, host
defense, or antitumor immunity (Martinez et al., 2008;
Sica and Mantovani, 2012). In contrast, M2F are activated
by IL4, IL10, or M-CSF; regulate wound healing; and sup-
press T cell and host defense responses as well as antitumor
immunity. Thus, we analyzed terminal differentiation
along the monocyte/macrophage pathway in IL-3/M-CSF
exposed cells and used PB monocytes polarized with
either GM-CSF or M-CSF as controls for M1F or M2F,
respectively.
Hematopoietic differentiation of iPSCs in the presence of
IL-3/M-CSF resulted in the continuous production of cells
by MCFCs for more than 2 months at a quantity of 5 3
105 to 13 106 cells/week/well (Figure 2A). Of note,myeloid
cells could be harvested for up to 4–5 months before the
cultures were exhausted. Cells in suspension were har-
vested twice a week and further differentiated in the pres-
ence of M-CSF only, resulting in adherent cells displaying
long filopodia typical of M2F (Rey-Giraud et al., 2012; Fig-
ure 2B). The morphology of iPSC-derived macrophages
(iPSC-MF) in culture resembled that of PB-derived M2F
(PB-M2F) and was in contrast to the round shape of M1F
generated from PB cells by GM-CSF exposure. Moreover,
cytospins of iPSC-MF displayed a classicalMFmorphology
indistinguishable from that of M1F or M2F control cellsStem Cellgenerated from the PB (Figure 2C). iPSC-MF, PB-M1F,
and PB-M2F all displayed big organelles (vacuoles), a phe-
nomenon frequently encountered in cell culture (also see
Figure 3A). Flow-cytometric surface phenotyping of iPSC-
MF revealed expression of classical MF markers such as
CD45, CD14, CD163, and CD86 similar to those of M2F
(Figure 2D), whereas surface markers associated with plu-
ripotency (TRA1-60), HSCs (CD34), B cells (CD19), or gran-
ulocytes (CD66b) were absent (Figure 2E).
A similar surface marker pattern was observed for macro-
phages derived from the human PSC line H9 (Figures S3A
and S3B) or a second iPSC line (hCD34iPSC11) generated
from human CD34+ cells (Figures S4A and S4B).
Of note, cells that recovered directly from theMCFC (end
of step 3) and analyzed prior to terminal differentiation
showed a clearly reduced CD14 and CD163 expression
compared with iPSC-MF that differentiated for a further
7 days (step 4; Figures S5A and S5B). These findings high-
light the need for terminal MF differentiation in the pres-
ence of high concentrations of M-CSF.
Functional Characterization of M-CSF-Primed
iPSC-MF
In order to investigate the in vitro functionality of iPSC-
MF, we analyzed cells for their ability to phagocytose latex
beads or gold particles. As depicted in Figure 3A, electron
microscopy revealed the ability of iPSC-MF to phagocytose
latex beads (red arrow) and gold particles (green arrow) as
efficiently as PB-M1F or PB-M2F (employed as controls).
In addition, almost all phagosomes in iPSC-MF were co-
localized with gold particles, indicating normalmaturation
by late endosome/lysosome fusion. Quantification of
phagocytic efficiency by uptake of fluorescence-labeled
latex beads revealed 90% positively labeled iPSC-MF or
H9-derived macrophages, comparable to PB-M2F, whereas
only60%of PB-M1Fwere positive for latex beads (Figures
3B and S3C). Furthermore, we exposed iPSC-MF and cells
freshly recovered from MCFC cultures to bacterial LPS to
investigate the induction of pro-inflammatory cytokines
and chemokines. Upon LPS stimulation, both iPSC-derived
cell sources (fresh and terminally differentiated cells) pro-
duced IL-8 in similar quantities compared with the PB-
M1F and PB-M2F controls, whereas release of IL1-b, IL-4,
IL-5, IL-12p70, or IL-13 was hardly detectable (Figures 3C
and S5C). Moreover, iPSC-MF and freshly MCFC-derived
cells produced IL-6 and IL-10 at much higher levels than
PB-M1F and PB-M2F, respectively. Of note, iPSC-MF and
freshly MCFC-derived cells also secreted tumor necrosis
factor alpha (TNF-a) and the chemokinemonocyte chemo-
tactic protein 1 (MCP-1), indicating a high capacity of these
cells to induce inflammatory processes and monocyte
attraction (Figures 3C and S5C), and a secretion pattern in-
termediate between M1F and M2F.Reports j Vol. 4 j 282–296 j February 10, 2015 j ª2015 The Authors 285
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Figure 2. Phenotypical Characterization of iPSC-MF
(A) Quantities of monocyte/macrophages harvested from the supernatant at different days of differentiation (step 3). Quantities are given
for one well of a six-well plate (n = 2 independent experiments, mean ± SD).
(B) Light microscopy of PB-derived macrophages (PB-MF) polarized with GM-CSF to M1F (top left), or with M-CSF to M2F (top right) and
iPSC-MF (end of step 4, bottom panels; scale bar, 200 mM).
(C) Cytospins of PB-MF polarized to M1F (top left) or M2F (top right) and iPSC-MF (end of step 4, bottom panels; scale bar, 0.01 mM).
(D) Surface marker expression of typical MF maker (CD45, CD11b, CD14, CD163, and CD86; blue filled) on PB-M1F, PB-M2F, or iPSC-MF
(end of step 4) analyzed by flow cytometry (red, respective isotype control).
(E) Surface marker expression of TRA-1-60, CD34, CD19, and CD66b (blue filled) on PB-M1F, PB-M2F or iPSC-MF (end of step 4) analyzed
by flow cytometry (red, respective isotype control). Data are shown for hCD34iPSC16.
See also Figures S3–S5.G-CSFDirects hiPSCs toward aGranulocyte Phenotype
Given the importance of G-CSF in directing multipotent
HSCs toward a granulocyte lineage, we investigated the ef-
fect of G-CSF on the in vitro hematopoietic differentiation
of hiPSCs by substituting M-CSF with G-CSF in our stan-
dard differentiation protocol. Similar to what was observed
for the generation of macrophages, the IL-3/G-CSF combi-
nation resulted in the formation of MCFCs from settled
EBs, which was observed within 10–15 days (Figure 4A).
Again, the formation of endothelial-like stromal cells pro-286 Stem Cell Reports j Vol. 4 j 282–296 j February 10, 2015 j ª2015 The Avided a quality criterion for the success of hematopoietic
differentiation. After 13–16 days of IL-3/G-CSF exposure,
shedding of round-shaped cells from the MCFCs was
observed (Figure 4A). These cells could be harvested twice
a week at a quantity of 4–5 3 106 cells/well/week for
R7 weeks (Figure 4B). However, after 2–3 months, the
number of cells harvested from the supernatant gradually
decreased, indicating culture exhaustion. Further differ-
entiation of these cells in high concentrations of G-
CSF for 7 days yielded cells of granulocyte morphologyuthors
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Figure 3. Functional Characterization of iPSC-MF
(A) Electron microscopy of latex-bead-containing phagosomes in M1F (top left), M2F (top center), and iPSC-MF (end of step 4, top right;
scale bar, 5 or 10 mM), and higher magnifications of latex-bead-containing phagosomes (bottom row; scale bar, 1 mM). Red arrows indicate
latex-bead-containing phagosomes. Green arrows indicate gold particles (5 nM) localized within a latex-bead-containing phagosome.
(B) Phagocytosis of fluorescein isothiocyanate (FITC)-labeled latex beads by control cells (undifferentiated iPSCs), PB-M1F, PB-M2F, or
iPSC-MF (end of step 4) analyzed by flow cytometry. Left: diagrams of a representative experiment (blue filled, cells treated with 1 mm
beads; red, untreated control. Right graph: percentage of phagocytosing cells (n = 3 independent experiments; mean ± SD of independent
experiments; significance was calculated by one-way ANOVA with Tukey’s post hoc test).
(C) Cytokine production of PB-M1F, PB-M2F or iPSC (end of step 4) upon stimulation with LPS (n = 3 technical replicates, mean ± SD).
Data are shown for hCD34iPSC16.
See also Figure S5.
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Figure 4. Phenotypical Characterization of iPSC-Gra
(A) Light microscopy of an MCFC generating iPSC-Gra (step 3; scale bar, 500 and 100 mM).
(B) Amount of granulocytes harvested from the supernatant at different days of differentiation (step 3; n = 2 independent experiments,
mean ± SD). Quantities are given for one well of a six-well plate.
(C) Cytospins of PB-Gra and iPSC-Gra (end of step 4). Scale bars, 10 mM (black) and 20 mM (blue).
(D) Representative images for iPSC-Gra (end of step 4) resembling different maturation stages of granulopoiesis (magnification: 1003).
(E) Differential count of cytospins from iPSC-Gra. Data are shown for hCD34iPSC16.
See also Figure S7.(iPSC-Gra) closely resembling PB-Gra (Figure 4C). Accord-
ing to May-Giemsa-stained cytospins, iPSC-Gra reflected
all stages of terminal granulocyte differentiation (average),
including pro-myelocytes (4%), myelocytes (6%), meta-
myelocytes (29%), n-banded neutrophils (22%), and seg-
mented neutrophils (36%), as well as mature basophils
(1%) and eosinophils (2%) (Figures 4D, 4E, and S6A).
When analyzed by flow cytometry, iPSC-Gra were found
to express the classical granulocyte surface markers CD45,
CD11b, CD16, and CD66b, although in relation to PB-288 Stem Cell Reports j Vol. 4 j 282–296 j February 10, 2015 j ª2015 The AGra, expression of CD11b, CD16, and CD66b was reduced
(Figure 5A). This most likely reflects a failure of the in vitro
differentiation process to completely recapitulate in vivo
granulocyte maturation. This observation became even
more prominent in cells that were harvested from the dif-
ferentiation culture directly after they were shed from the
MCFC (end of step 3) without further maturation in
high-dose G-CSF (Figure S6B). In these cells, expression of
CD16 and CD66b was even further reduced, although
cells uniformly stained positive for CD45 and CD11buthors
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Figure 5. Surface Marker Profile of iPSC-Gra
(A) Surface marker expression of typical granulocytic maker (CD45, CD11b, CD16, and CD66b; blue filled) on PB-Gra or iPSC-Gra (end of step
4) analyzed by flow cytometry (red, respective isotype control).
(B) Surface marker expression of TRA-1-60, CD34, CD19, CD14, and CD163 (blue filled) on PB-Gra or iPSC-Gra (end of step 4) analyzed by
flow cytometry (red, respective isotype control). Data are shown for hCD34iPSC16.
See also Figures S6 and S7.(Figure S6B). Similar to what was observed for iPSC-MF,
iPSC-Gra and freshly MCFC-derived cells stained negative
for the surface markers TRA1-60, CD34, and CD19, and
the macrophage markers CD14 and CD163, further high-
lighting the granulocytic differentiation (Figures 5B and
S6C).
We obtained similar results upon granulocytic differenti-
ation with an iPSC line that was originally generated from
human fibroblasts, employing a lentiviral reprogramming
cassette. Subsequently, we excised the reprogramming
cassette using Flp-recombinase and frt sites to obtain a
transgene-free iPSC line (Kuehle et al., 2014). In the plurip-
otent state, this line demonstrated typical morphology and
expressed typical pluripotency-associated surface markers,Stem Cellsuch as TRA1-60 and SSEA4 (A.S. and D.H., unpublished re-
sults; Figures S7A and S7B). Hematopoietic differentiation
in our myeloid differentiation model utilizing IL-3/G-CSF
resulted in cells with a classical granulocytic morphology,
as shownon brightfield and cytospin images, aswell as pos-
itive antigens for CD45 and CD66b (Figures S7C and S7D).
Functional Characterization of G-CSF-Primed
iPSC-Gra
Given the classical morphology and cell-surface-marker
phenotype of iPSC-Gra, we next assessed their function-
ality following a 7-day exposure to high-level G-CSF.
First, we investigated the capacity of iPSC-Gra to
generate hydrogen peroxide during the oxidative burst.Reports j Vol. 4 j 282–296 j February 10, 2015 j ª2015 The Authors 289
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Figure 6. Functional Characterization of iPSC-Gra
(A) Dihydrorhodamine (DHR) assay measuring the production of reactive oxygen species (ROS) after activation with phorbol myristate
acetate (PMA) in PB-Gra or iPSC-Gra by flow cytometry (n = 3 of independent experiments; mean ± SEM).
(B) Time dependence of ROS production in PB-Gra or iPSC-Gra after PMA stimulation measured by conversion of DCFDA to luminescent DCF
(n = 1 for PB-Gra; n = 2 independent experiments, mean ± SD for iPSC-Gra).
(C) Migration potential of PB-Gra or iPSC-Gra toward an fMLP or hIL-8 gradient (n = 3 independent experiments; mean ± SD). Values are
given as fold change over nonstimulated cells.
(D) Confocal fluorescence microscopy of NET formation by PB-Gra (top row) or iPSC-Gra (bottom row) after stimulation with PMA. Images
represent nuclear-DAPI staining (blue) and ELA staining (green), as well as overlays (scale bar, 10 mM).
(E) Phagocytosis of FITC-labeled latex beads, PB-Gra, or iPSC-Gra analyzed by flow cytometry (a representative experiment is shown; blue
filled, untreated control; red, cells treated with 1 mm beads). Data are shown for hCD34iPSC16.We measured hydrogen peroxide activity indirectly by
assessing the oxidation of nonfluorescent dihydrorhod-
amine 123 (DHR 123) to fluorescent rhodamine 123. As de-
picted in Figure 6A, only baseline rhodamine expression
was detected in iPSC-Gra and PB-Gra (serving as positive
controls). Upon activation of iPSC-Gra with phorbolmyris-
tate acetate (PMA), however, 90% of iPSC-Gra stained
positive for rhodamine comparably to PB-Gra controls (Fig-
ure 6A). Similarly, upon activation with PMA, iPSC-Gra
showed robust reactive oxygen species (ROS) induction,
as measured by the conversion of dichlorofluorescein diac-
etate (DCFDA) to the cell-impermeable and fluorescent dye
dichlorofluorescein (DCF) (Figure 6B). At all PMA concen-
trations investigated, iPSC-Gra induced significant levels
of ROS within 2–6 hr, with close to plateau levels reached290 Stem Cell Reports j Vol. 4 j 282–296 j February 10, 2015 j ª2015 The Aafter 22–34 hr. Although this time course largely recapitu-
lated the ROS response of PB-Gra control cells, the overall
ROS levels achieved in iPSC-Gra were reduced by 50%.
iPSC-Gra were also able to actively migrate toward an
IL-8 or N-formyl-methionyl-leucyl-phenylalanine (fMLP)
gradient, and their migratory capacity was increased by
2-fold in comparison with their nonstimulated counter-
parts. Nevertheless, this property was clearly reduced in
comparison with PB-Gra, which showed a 6- to 7-fold in-
crease in mobility upon IL-8 or fMLP stimulation (Fig-
ure 6C). In addition, iPSC-Gra were able to form neutrophil
extracellular traps (NETs) for extracellular pathogen killing.
As illustrated in Figure 6D, neutrophil-elastase (ELA)
expression in iPSC-Gra and PB-Gra co-localized with
nuclear-DAPI staining under nonstimulated conditions,uthors
whereas upon stimulation with PMA, both cell types un-
derwent characteristic changes in intracellular architecture
and expelled their chromatin to form NETs, although this
reaction was more pronounced in PB-Gra. Moreover,
granulocytes represent professional phagocytes with the
capacity to clear pathogens upon stimulation, as assessed
by their ability to take up fluorescence-labeled beads. Also
in this assay, iPSC-Gra demonstrated functional activity
at least as good as that of PB-Gra (52% versus 72% uptake
of latex beads, PB-Gra versus iPSC-Gra, respectively;
Figure 6E).Generating Macrophages and Granulocytes by Using
GM-CSF
Finally, we investigated the effect of GM-CSF on
hCD34iPSC16 in our myeloid differentiation protocol. He-
matopoietic differentiation of iPSCs in the presence of IL-3/
GM-CSF generated MCFCs with the same efficacy as
observed with the M-CSF/IL-3 or G-CSF/IL-3 combination,
and round-shaped cells were shed 10–15 days after cyto-
kine application (Figure 7A). Thereafter, cells produced by
the MCFCs were harvested continuously at a quantity of
43 105 cells/week/well. Of note, FACS analysis of freshly
isolated cells revealed two populations expressing either
CD45+, CD11b+, CD14+, and CD163+ (population 1; Fig-
ure 7B, top row) or CD66b/dim, CD45+, and CD11b+
(population 2; Figure 7B, bottom row) surface markers. Dif-
ferentiation of cells in 100 ng/ml GM-CSF for 7 more days
provided both suspension and adherent cells (Figure 7C)
with a granulocyte or macrophage morphology detected
by cytospin (Figure 7D). On flow cytometry, this popula-
tion expressed the surface markers CD66bdim, CD14,
CD163, CD16, CD45, and CD11b, though to various ex-
tents (Figure 7E).DISCUSSION
Hematopoietic differentiation of human PSCs represents a
highly complex and finely tuned process in which the
interaction of different cytokines, matrix factors, cell types,
signaling pathways, and transcription factors results in
specialized cells of the hematopoietic lineage (Clarke
et al., 2013; Sumi et al., 2008). In this study, we provide
experimental evidence that a combination of IL-3/G-CSF
or IL-3/M-CSF in vitro is sufficient to drive differentiation
of hiPSCs toward functional cells of granulocyte or mono-
cyte/macrophage lineage. As amatter of fact, when only G-
CSF was used, lower cell shedding from the MCFC was
observed (data not shown). This implies that IL-3 is critical
for the early part of this process. In the context of adult
hematopoiesis, IL-3 has been demonstrated to support
myelopoiesis, specifically when combined with otherStem Cellgrowth factors such as G-CSF or GM-CSF, and later work es-
tablished its efficacy on the stem and early progenitor cell
level (Donahue et al., 1988; Krumwieh et al., 1990). Simi-
larly, a cooperative effect of IL-3 with cytokines such as
IL-1, M-CSF, GM-CSF, and erythropoietin on both myeloid
and erythroid in vitro differentiation of ESCs has been
described (Wiles and Keller, 1991). More recently, IL-3
was also demonstrated to promote the development of
HSCs in the yolk sac and the aorta-gonad-mesonephros
(AGM) region of murine embryos, and a role of this cyto-
kine in proliferation or survival of early HSCs was postu-
lated (Robin et al., 2006). Given these results, our finding
that IL-3 has a profound effect on the hematopoietic differ-
entiation process comes as no surprise. Moreover, our own
unpublished data suggest that IL-3 also cooperates with
IL-4 in generating dendritic cells from hiPSCs, further sup-
porting a pivotal role of IL-3 during hematopoietic in vitro
differentiation of human PSC sources.
Clearly, in our hands, the formation of an endothelial-
like stromal cell layer by the MCFC was predictive for
successful hematopoietic differentiation later on. Although
the requirement of endothelial support and even endothe-
lial origin (hemogenic endothelium) for definitive hemato-
poiesis has been firmly established (Choi et al., 2012;
Clarke et al., 2013; Kennedy et al., 2007; Sturgeon et al.,
2014), it appears unlikely that the endothelial-like stromal
cells that anchored the EBs to the plates in our cultures
directly interact with the primitive cells within the MCFC
that is responsible for the continuous output of hemato-
poietic cells. A much more likely explanation is that also
within the MCFC, endothelial stromal cell support is
required for efficient hematopoietic differentiation, and
the endothelial-like stromal cell layer on the outside func-
tions as an indicator of the efficacy of this interaction (San-
dler et al., 2014).
Based on their well-documented activity profile, we
employedM-CSF and G-CSF to direct terminal myeloid dif-
ferentiation toward themonocyte/macrophage or granulo-
cyte lineage in our studies. We found that the IL-3/M-CSF
combination efficiently promoted the differentiation of
iPSCs into iPSC-MF that resembled PB-MF in terms
of morphology, surface phenotype, cytokine secretion
potential, and phagocytic activity. Interestingly, iPSC-MF
displayed surface marker expression and phagocytic prop-
erties similar to (alternatively) M2-polarized MF in the
PB. In this respect, iPSC-MF strongly expressed CD14
and CD163, and showed a high capacity for latex bead
phagocytosis similar to PB monocytes polarized to M2-F
byM-CSF. However, with regard to a number of other char-
acteristics, the cells that were recovered by our in vitro dif-
ferentiation protocol did not strictly follow the dichotomy
ofM1 versusM2 polarization. Thus, CD86 (B7-2) was high-
ly expressed on our iPSC-MF, a surface marker typicallyReports j Vol. 4 j 282–296 j February 10, 2015 j ª2015 The Authors 291
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associated with pro-inflammatory M1F. However, this
might be explained by the in vitro differentiation of our
iPSCs using final differentiation medium (Rey-Giraud
et al., 2012). Moreover, when we investigated secretion of
pro- and anti-inflammatory cytokines and chemokines
upon LPS stimulation, iPSC-MF showed secretion of TNF-
a, MCP1, IL-6, IL-8, and IL-10 at levels indicating profound
activation. Although M2F are known to be stimulated by
LPS, classification of our iPSC-MF according to the M1/
M2 scheme based on their chemokine release pattern ap-
pears problematic. LPS induces upregulation of its receptor,
CD14 (Landmann et al., 1996; Meng and Lowell, 1997), in
M1F and M2F, which then typically express TNF-a, IL1,
and IL-6 (M1F), or TGF-b and IL-10 (M2F) (Cella et al.,
1997; Hao et al., 2012; Lacey et al., 2012; Martinez et al.,
2008). However, these patterns are by no means exclusive.
Thus, for M2 polarization, various subtypes (M2a–c) with
altered secretion patterns have been described, and further-
more, mixtures of M1 and M2 patterns may co-exist (Jones
and Ricardo, 2013). Thus, the nonclassical secretion
pattern of iPSC-MF is not surprising. Independently of
their M1/M2 specification, however, iPSC-MF constitute
remarkably active MF and a highly interesting source for
potential cell-therapy approaches (e.g., for infections and
malignant diseases). In this context, the high IL-8 levels
that were induced in these cells are of considerable interest
because this cytokine is a major chemotactic agent for re-
cruiting granulocytes and other effector immune cells to
the site of activity (Harada et al., 1994).
In a similar way, differentiation of iPSCs utilizing the
IL-3/G-CSF combination resulted in granulocytes that
mimicked the characteristic features of PB-Gra, such as sur-
face marker expression, respiratory burst activity, forma-
tion of NETs, and migratory and phagocytotic capacity.
Moreover, iPSC-Gra displayed all stages of terminal granu-
locyte maturation, ranging from the promyelocyte to
the segmented-cell stage, a phenomenon that ismost likely
explained by the continuous shedding of less differentiated
granulocyte lineage cells from the MCFC, which then
furthermaturate in suspension culture. In linewith this hy-
pothesis, cells directly isolated fromMCFC cultures showed
a more immature surface phenotype with reduced CD16
(Fc gamma RIII), and CD66b (also known as CD67, NCA-
95, or CGM6) expression, whereas expression of these
markers increased upon exposure to G-CSF for 7 moreFigure 7. Generation of Granulocytes or Macrophages by GM-CSF
(A) Formation of an MCFC by addition of GM-CSF and IL-3 to differen
(B) Flow-cytometric analysis of cells freshly isolated from the MCFC (st
1 (top row) or population 2 (bottom row; red line represents isotype
(C–E) Brightfield (C; scale bars, 1,000 and 200 mM) and cytospin imag
analysis (E) of cells harvested from the MCFC in the presence of GM-CS
CSF (end of step 4; red line represents isotype controls, blue line rep
Stem Celldays. In the human in vivo setting, expression of CD15 is
associated with blast to pro-myelocyte differentiation,
whereas CD66b and CD16 appear in pro-myelocytes to
meta-myelocytes and persist to the segmented stage (Elghe-
tany, 2002). However, iPSC-derived granulocytes also dis-
played certain functional deficiencies when compared
with their PB counterparts. This was particularly obvious
in their capacity to migrate toward IL-8 or fMLP gradients.
Expression of the IL-8 receptor (CXCR2) on mature rather
than immature granulocytes has been described (Nguyen-
Jackson et al., 2010). Despite many similarities, exposing
iPSC-Gra to G-CSF for 7–10 days might not be sufficient
to drive granulopoiesis from iPSCs in vitro toward termi-
nally differentiated cells. In this regard, either sorting cells
for a more mature marker profile (CD15/CD16) or an addi-
tional cultivation of cells in G-CSF in combination with
other differentiation stimuli, such as transferrin (Evans
et al., 1986), may allow for the generation of more func-
tional cells. Although the number of granulocytes reached
0.5 3 106/well/week in a laboratory scale, both more
advanced scale-up techniques and GMP-grade final he-
matopoietic differentiation should be investigated before
this protocol is extended to clinical applications. This is
highly relevant given that granulocyte transfusion is per-
formed with a minimal cell dose of 2–3 3 1010 (Lee et al.,
2001).
In this work, we developed an innovative hematopoietic
differentiation protocol that allows for the large-scale gen-
eration of functional,maturemyeloid cells such as granulo-
cytes or macrophages from single cultures over prolonged
time periods. As an advantage in comparison with other
protocols in the field, our protocol combines minimal
cytokine support and hence a reduced complexity of the
procedure with high and long-term cellular output. Even
more importantly, our protocol allows one to generate
different mature myeloid cell types by simply changing
the cytokine support in the differentiationmedium. There-
fore, we expect it will also be suitable for producing other
cell types, such as dendritic cells, platelets, andmegakaryo-
cytes. Clearly, a more precise characterization of the iPSC-
derived myeloid cells by genome-wide expression analysis
(which we have already initiated) is the next important
step from a scientific perspective and is a prerequisite for
potential clinical applications. Given theminimal addition
of external cytokines, this protocol also appears to betiation medium I.
ep 3). Cells were pre-gated according SSC/FSC gating for population
controls, blue line represents antigen).
es (D; scale bars, 10 [black] and 20 mM [blue]), and flow-cytometric
F/IL-3 and further differentiated in the presence of 100 ng/ml GM-
resents antigen). Data are shown for hCD34iPSC16.
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particularly suited to gain further insights into hiPSC-based
hematopoietic in vitro differentiation and its relation to
the corresponding in vivo processes that take place in the
embryo. Given the efficacy of the in vitro process, the pro-
tocol also appears to be useful for future cell-replacement or
cell-based gene-therapy strategies based on terminally
differentiated myeloid cells.EXPERIMENTAL PROCEDURES
Hematopoietic Differentiation of hiPSCs
We performed hematopoietic differentiation of hiPSCs using a
modified version of the EB-based hematopoietic differentiation
protocol described previously (Lachmann et al., 2014; vanWilgen-
burg et al., 2013). In brief, PSC colonies were disrupted to frag-
ments using collagenase-V, and EB formationwas induced by culti-
vation for 5 days in ESC medium supplemented with 10 ng/mL
bFGF and 10 mM Rock inhibitor (Y-27632; Tocris) in six-well
suspension plates on an orbital shaker (100 rpm). After manual
transfer of EBs onto tissue culture six-well plates and cultivation
in differentiation medium I (APEL medium; Stem Cell Technolo-
gies) supplemented with 1% penicillin-streptomycin (Life Tech-
nologies), 25 ng/ml human IL-3 (hIL-3) and 50 ng/ml human
M-CSF (hM-CSF), human G-CSF (hG-CSF), or human GM-CSF
(hGM-CSF; all from Peprotech), MCFCs were generated from the
attached EBs within 7 days. From d10–d15 onward, monocytes/
macrophages or granulocytes generated by the MCFCs were har-
vested twice a week from the supernatant and filtered through
a 150-mMmesh. For furthermaturation,monocytes/macrophages
or granulocytes were cultured in differentiation medium II
(RPMI1640 medium supplemented with 10% fetal serum, 2 mM
L-glutamine, 1% penicillin-streptomycin, and 100 ng/ml hM-
CSF, hG-CSF, or hGM-CSF, respectively) for 7–10 days.
Phagocytosis Assay
For analysis of phagocytosis, cells were cultured overnight in 96-
well plates at a concentration of 13 105 cells/ml in RPMI1640me-
dium supplemented with 10% fetal serum, 2 mM L-glutamine, 1%
penicillin-streptomycin, and 100 ng/ml hM-CSF. The next day,
carboxylate-modified red fluorescent latex beads with a mean
diameter of 1 mm (L3030; Sigma-Aldrich) were added at a concen-
tration of 1:200, and the cells were incubated with or without
beads for 2 hr. After repeated washing, the cells were analyzed by
flow cytometry.
Immunostaining of NETs
NET formation was analyzed using confocal laser-scanning micro-
scopy. Neutrophils were suspended in RPMI and treated with
either PMA (16 nM) or medium on coverslips and incubated for
4 hr at 37C. Specimens were washed with warm PBS, fixed with
3% PBS-buffered formaldehyde, and permeabilized with 0.5%
Triton X-100 in PBS. After blocking with 5% BSA, ELA was labeled
using the monoclonal mouse anti-human ELA clone NP57 (Dako)
primary antibody. Secondary antibody was conjugated with Alexa
Fluor-488 (anti-mouse, catalog no. A11001; Invitrogen Life Tech-
nologies) and DAPI (catalog no. P36935; Sigma-Aldrich). Slides294 Stem Cell Reports j Vol. 4 j 282–296 j February 10, 2015 j ª2015 The Awere analyzed using an Olympus FluoView confocal laser-scan-
ning microscope in sequential scanning mode for two channels.SUPPLEMENTAL INFORMATION
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